Since it was previously shown that ML323 treatment causes replication stress and cisplatin sensitization in certain cancer cells (64,75), our findings suggest that the development of USP1 inhibitors for their potential use in cancer treatment (57) should be carefully evaluated to take into consideration the impact of the genetic background. This evidence concerns the gene USP1 and cancer.